Find and Pitch Jounalists, Get Your Story Covered

Tags: cabozantinib atezolizumab prostate cancer docetaxel castrate-resistant prostate cancer

	Profile	Recent Articles on Subject
1	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Inebilizumab for Myasthenia Gravis Reduces Steroid Burden - 12 days ago Cabozantinib Plus Atezolizumab Improves PFS in Metastatic CRPC - 9 months ago Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients - 11 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - 11 months ago Dato-DXd More Effective, Tolerable Than Chemo for Metastatic Breast Cancer - 11 months ago Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years - 11 months ago T-DXd Could Be 'Practice-Changing' in HER2-Expressing Gynecologic Cancers - 12 months ago New Data on Bimekizumab in Psoriatic Arthritis - 12 months ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - 12 months ago Tralokinumab Controls Moderate-to-Severe AD Over the Long Term - 12 months ago Anti-TIGIT Drug Fails to Lift Response Rates in Cervical Cancer Trial - 12 months ago IL-13 Blocker for Eczema Maintains Efficacy at Less-Frequent Dosing - about 1 year ago
2	Kristen Monaco MedPage Today	Complement Inhibitor Shows Promise for Rare Kidney Disorder - 21 days ago
3	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Another Win for Antibody-Drug Conjugate in HER2+ Breast Cancer With Brain Mets - 2 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 2 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 3 months ago Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC - 9 months ago Cabozantinib Plus Atezolizumab Delays Progression in mCRPC - 10 months ago Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer - 10 months ago Atezolizumab Plus Carboplatin Boosts Survival in Metastatic TNBC - 11 months ago Axatilimab Shows Efficacy in Recurrent/Refractory GVHD - 11 months ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - about 1 year ago
4	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Lebrikizumab Wins FDA Approval for Eczema - 2 months ago FDA OKs Amivantamab as First-Line Lung Cancer Treatment - 9 months ago New Options Challenge Standard Treatments in EGFR-Mutant NSCLC - about 1 year ago Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years - about 1 year ago
5	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Exploratory Analysis Shows Favorable Outcomes for Amivantamab-Lazertinib Treatment in NSCLC - 2 months ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 3 months ago FDA Approves Epcoritamab for Treatment of Relapsed, Refractory Follicular Lymphoma - 5 months ago FDA Accepts sBLA for Bimekizumab-bkzx in Hidradenitis Suppurativa Treatment - 8 months ago Study: Lebrikizumab Demonstrates Improvements in Atopic Dermatitis for Patients of Color - 8 months ago FDA Approves Tocilizumab-aazg as Biosimilar to Actemra for Multiple Indications - 9 months ago FDA Grants Priority Review to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma - 9 months ago Biosimilar Adalimumab, Etanercept Have Equivalent Effectiveness to Reference Drugs Over 48 Months - 9 months ago Biosimilar SB8 Is Comparable to Bevacizumab for Non–Small Cell Lung Cancer - 9 months ago Celltrion Seeks Approval From FDA for CT-P47 as Biosimilar of Tocilizumab - 10 months ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - about 1 year ago
6	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	MHRA approves Astellas’ Vyloy combination for gastric cancer - 3 months ago
7	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Amgen’s trial brings new hope for IgG4-RD patients - 6 months ago
8	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	AstraZeneca, Daiichi Sankyo Drug Enhertu Becomes First Tumor-Agnostic ADC Cancer Med - 7 months ago
9	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors - 8 months ago FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy - 8 months ago
10	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Approves Expanded Indications for Spesolimab-sbzo Injection for the Treatment of Generalized Pustular Psoriasis - 8 months ago Risankizumab Significantly Reduces Severity of Psoriasis Symptoms - 8 months ago FDA Accepts BLA for Datopotamab Deruxtecan for the Treatment of NSCLC - 9 months ago

Journalists covering atezolizumab